Aventis Pasteur MSD Adds Chiron's Meng C and Flu Vaccines To Portfolio
Executive Summary
Aventis Pasteur MSD will sell Chiron's meningococcal C vaccine Menjugate and adjuvanted influenza vaccine Fluad under a co-marketing agreement.
You may also be interested in...
Chiron Acquiring PathoGenesis For Six Times Consensus 2001 Revenues
Chiron will pay about 6.1 times PathoGenesis' consensus 2001 revenues when it acquires the company for approximately $700 mil. cash.
Chiron Acquiring PathoGenesis For Six Times Consensus 2001 Revenues
Chiron will pay about 6.1 times PathoGenesis' consensus 2001 revenues when it acquires the company for approximately $700 mil. cash.
Baxter Acquisition Of NAVA Hinges On Approval of NeisVac-C in U.K.
Baxter's acquisition of North American Vaccine is contingent upon the U.K. approval of NAVA's group C meningococcal conjugate vaccine NeisVac-C.